Compare OREX to:
After Hours: 6.8986 N/A (N/A) 1:17pm ET
| Last Trade: | 6.90 |
|---|---|
| Trade Time: | Nov 27 |
| Change: | |
| Prev Close: | 7.05 |
| Open: | 6.80 |
| Bid: | 6.56 x 300 |
| Ask: | N/A |
| 1y Target Est: | 13.67 |
| Day's Range: | 6.72 - 6.95 |
|---|---|
| 52wk Range: | 1.55 - 10.83 |
| Volume: | 276,225 |
| Avg Vol (3m): | 892,185 |
| Market Cap: | 324.58M |
| P/E (ttm): | N/A |
| EPS (ttm): | -2.01 |
| Div & Yield: | N/A (N/A) |
| Sat 10:34am | 12 Years Of Patent Protection For Biologics Based Research And Development Creates Buying Opportunity In Biotech StocksWall Street Transcript |
| Wed, Nov 25 | Founder Scott Cook Sells $14.7M Worth of IntuitTheStreet.com |
| Tue, Nov 24 | OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and EEDGAR Online |
| Tue, Nov 24 | Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)PR Newswire |
| Mon, Nov 23 | The Side Effect of Developing Obesity Drugsat Motley Fool |
| Mon, Nov 23 | Poniard Finds Cash to Keep Lights On: BioBuzzat TheStreet.com |
| Mon, Nov 23 | Cel-Sci Chairman Sells Stock, Despite Sweetheart Loan Deal: BioBuzzat TheStreet.com |
| Mon, Nov 23 | FDA Issues New Obesity Drug Heart Warning: BioBuzzat TheStreet.com |
| Mon, Nov 23 | Four Senior Executives Join Orexigen(R) Therapeutics Management TeamPR Newswire |
| Wed, Nov 18 | Obesity and ED: Two Big Markets, One Tiny Companyat Minyanville.com |
Quotes delayed, except where indicated otherwise.
Delay times are 15 mins for NASDAQ, NYSE and Amex.See also delay times for other exchanges.